Comparing the Efficiency of Combination of Minoxidil Solution and Tacrolimus Cream with Minoxidil Solution Alone in the Treatment of Alopecia Areata

Document Type : Original Article (s)

Authors

1 Professor, Skin Diseases and Leishmaniasis Research Center AND Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Skin Diseases and Leishmaniasis Research Center AND Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Associate Professor, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

5 Student of Medicine, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Alopecia areata is an idiopathic disease in which there is patchy hair loss. Many treatments for hair loss coin (less than 50% hair loss) has been proposed Including corticosteroid injections, topical 5% minoxidil, and anthralin cream or ointment on the skin without hair. Since recent studies on the role of autoantibodies and autoimmune disease in alopecia areata have raised and the drugs used in its treatment are immunomodulators, this study aimed to compare the efficiency of tacrolimus and minoxidil with minoxidil alone in the treatment of alopecia areata.Methods: This randomized, double-blind clinical trial study was done in Alzahra Hospital and Sedigheh Tahira Center of Dermatology and Leishmaniasis, affiliated to Isfahan University of Medical Sciences, from September 2012 to September 2013. In this study, 96 lesions in 54 patients with alopecia areata with various size and number of lesions were studied in two treatment groups. One group recived minoxidil 5% solution and tacrolimus 0.1% cream, and the other received minoxidil 5% solution and placebo cream. The mean lesion area at the onset of treatment, one and two months after starting the treatment, and one and three months after ending the therapy were measured  compared between the groups in both sexes and various ages.Findings: After the treatment, the lesions in group minoxidil and tacrolimus increased and in the group treated with placebo cream and minoxidil solution decreased.Conclusion: In our study, minoxidil 5% solution alone was more effective in treatment of alopecia areata compared to combination of minoxidil 5% solution and tacrolimus 0.1% cream.

Keywords

References

  1. Ali A, Martin JM. Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. J Drugs Dermatol 2010; 9(1): 62-4.
  2. Hon KL, Leung AK. Alopecia areata. Recent Pat Inflamm Allergy Drug Discov 2011; 5(2): 98-107.
  3. Schweiger ES, Boychenko O, Bernstein RM. Update on the pathogenesis, genetics and medical treatment of patterned hair loss. J Drugs Dermatol 2010; 9(11): 1412-9.
  4. Rastmanesh R. Alopecia and ocular alterations: a role for Minoxidil? J Recept Signal Transduct Res 2010; 30(3): 189-92.
  5. Firooz A, Firoozabadi MR, Ghazisaidi B, Dowlati Y. Concepts of patients with alopecia areata about their disease. BMC Dermatol 2005; 5: 1.
  6. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ, III. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995; 70(7): 628-33.
  7. Strober BE, Siu K, Alexis AF, Kim G, Washenik K, Sinha A, et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol 2005; 52(6): 1082-4.
  8. Epstein E. Evidence-based treatment of alopecia areata. J Am Acad Dermatol 2001; 45(4): 640-2.
  9. Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int J Dermatol 1996; 35(1): 22-7.
  10. McDonagh AJ, Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol 2002; 27(5): 405-9.
  11. de Berker DAR, Messenger AG, Sinclair RD. Disorders of hair. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's textbook of dermatology. 7th ed. Oxford, UK: Blackwell Science; 2004. p. 43-5, 63.
  12. Hunter N, Shaker O, Marei N. Diphencyprone and topical tacrolimus as two topical immunotherapeutic modalities. Are they effective in the treatment of alopecia areata among Egyptian patients? A study using CD4, CD8 and MHC II as markers. J Dermatolog Treat 2011; 22(1): 2-10.
  13. Freyschmidt-Paul P, Ziegler A, McElwee KJ, Happle R, Kissling S, Sundberg JP, et al. Treatment of alopecia areata in C3H/HeJ mice with the topical immunosuppressant FK506 (Tacrolimus). Eur J Dermatol 2001; 11(5): 405-9.
  14. Galadari I, Rubaie S, Alkaabi J, Galadari H. Diphenylcyclopropenone (diphencyprone, DPCP) in the treatment of chronic severe alopecia areata (AA). Eur Ann Allergy Clin Immunol 2003; 35(10): 397-401.
  15. Gilhar A, Landau M, Assy B, Shalaginov R, Serafimovich S, Kalish RS. Mediation of alopecia areata by cooperation between CD4+ and CD8+ T lymphocytes: transfer to human scalp explants on Prkdc(scid) mice. Arch Dermatol 2002; 138(7): 916-22.
  16. Spindler JR. The safety of topical minoxidil solution in the treatment of pattern baldness: the results of a 27-center trial. Clin Dermatol 1988; 6(4): 200-12.
  17. Lawrence ID. Tacrolimus (FK506): experience in dermatology. Dermatol Ther 1998; 5: 74-84.
  18. Freyschmidt-Paul P, Ziegler A, McElwee KJ, Happle R, Kissling S, Sundberg JP, et al. Treatment of alopecia areata in C3H/HeJ mice with the topical immunosuppressant FK506 (Tacrolimus). Eur J Dermatol 2001; 11(5): 405-9.
  19. McElwee KJ, Rushton DH, Trachy R, Oliver RF. Topical FK506: a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. Br J Dermatol 1997; 137(4): 491-7.
  20. Maurer M, Handjiski B, Paus R. Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. Am J Pathol 1997; 150(4): 1433-41.
  21. Jiang H, Yamamoto S, Kato R. Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant. J Invest Dermatol 1995; 104(4): 523-5.
  22. Yamamoto S, Jiang H, Kato R. Stimulation of hair growth by topical application of FK506, a potent immunosuppressive agent. J Invest Dermatol 1994; 102(2): 160-4.
  23. Herkal KC, Patil S, Yogeesh HR, Thimmappa RM, Cholachaguddar L. Study of therapeutic comparison of tacrolimus 0.1% and minoxidil 2% in alopecia areta. Our Dermatology Online 2013; 4(3): 306-10.
  24. Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol 1999; 135(5): 574-80.
  25. Price VH, Willey A, Chen BK. Topical tacrolimus in alopecia areata. J Am Acad Dermatol 2005; 52(1): 138-9.
Journal of Isfahan Medical School
Volume 31, Issue 269 - Serial Number 269
November and December 2014
Pages 2315-2325

Files

History

  • Receive Date: 30 January 2014
  • Revise Date: 02 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics